Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease

NCT ID: NCT02216877 Phase: PHASE1 Status: COMPLETED Enrollment: 36 Completion: 2015-04

Conditions

Chronic Kidney Disease, Hypomagnesemia

Interventions

Mablet 360 mg, Placebo

Summary

Randomized placebo-controlled interventional trial to investigate the effect of oral magnesium supplementation on intracellular magnesium in subjects with chronic kidney disease. We hypothesize that oral magnesium supplementation will increase intracellular magnesium in subjects with chronic kidney disease as well as increase serum magnesium.

Primary Outcome

Intracellular magnesium

Source

ClinicalTrials.gov